Embedded Files
About Olink
About Olink
Olink Proteomics is a next-generation affinity-based protein quantification platform designed to enable large-scale biomarker discovery and validation in clinical research. Built on the proprietary Proximity Extension Assay (PEA) technology, the platform allows simultaneous measurement of hundreds to thousands of proteins from a minimal sample volume of just a few microliters. This combination of high multiplexing capacity and low sample input requirement makes Olink particularly well-suited for studies involving precious or limited biospecimens such as plasma, serum, cerebrospinal fluid, and urine.
Quantified protein levels are reported as NPX (Normalized Protein eXpression) values on a relative log2 scale, allowing straightforward comparison across samples and cohorts. The current flagship panel, Olink Explore HT, covers more than 5,000 human proteins in a single run, providing a near-proteome-wide view of the circulating proteome. Together, these features position Olink as a powerful tool for translational research, enabling the identification of disease-associated protein signatures and the development of clinically actionable biomarkers.
Olink Explore HT at KNUH Proteomics Core is open to collaborators, to enquire please contact us.
download, the target biomarker assay list
Olink Explore HT
Olink Explore HT
Case include:
Disease biomarker discovery
Profile inflammatory mediators in disease
Identification of pQTL with GWAS study
For examples
Sun et al. (2023, Nature) - Plasma proteomic associations with genetics and health in the UK Biobank
Gong et al. (2025 Nature) - Multi-omic profiling reveals age-related immune dynamics in healthy adults
Ding et al. (2026, Nature Med) - Plasma proteomic signatures of cellular aging predict human disease
Olink scientific publications: here
The evolution of protein analysis technologies, from classical immunoassays to modern high-throughput affinity-based methods
Traditional approaches such as mass spectrometry offer theoretically unlimited target breadth but remain constrained in throughput and sample volume efficiency, whereas multiplexed immunoassay platforms like Luminex and MesoScale Discovery enable simultaneous analysis of tens of proteins with moderate throughput. More recently introduced affinity-based platforms, particularly Olink PEA and SomaLogic, demonstrate superior performance across most categories, with Olink PEA achieving top-tier ratings in all six metrics including throughput, sensitivity, specificity, and the ability to analyze over 5,400 proteins from minimal sample volumes. Together, these advances illustrate the field's trajectory toward simultaneously profiling thousands of proteins across thousands of samples with unprecedented sensitivity and analytical precision.
Page updated
Google Sites
Report abuse